NEWRON PHARMA N overview

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients 13.05.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients Further study analysis reveals...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients 30.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients Primary endpoint and key secondary endpoint of study met; drug was...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) 08.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Annual Report Newron presents 2023 financial results and provides 2024 outlook 19.03.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron presents 2023 financial results and provides 2024 outlook Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Financing Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement 15.03.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement EIB agrees to extend repayment dates of...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Financing Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million 14.03.2024 / 18:32 CET/CEST The issuer is solely responsible for the content of this announcement. Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares Proceeds of up to EUR 15.0* million Milan, Italy, March 14, 2024, 17:45 CET – Newron Pharmaceuticals S.p.A....